Protara Therapeutics (TARA) Net Equity Issued and Repurchased (2017 - 2020)

Protara Therapeutics' (TARA) quarterly Net Equity Issued and Repurchased came in at $48.3 million in Q4 2020, up 288.71% on a QoQ basis from $12.4 million in Q1 2020.

Protara Therapeutics (TARA) Net Equity Issued and Repurchased (2017 - 2020) Analysis & Trends

Protara Therapeutics (TARA) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $48.3 million in Q4 2020.

  • On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $48.3 million in Q4 2020; TTM through Dec 2020 was $60.7 million, a N/A change from a year earlier, with the FY2020 full-year figure at $73.6 million, changed N/A from the prior year.
  • Net Equity Issued and Repurchased for Q4 2020 stood at $48.3 million, up from $12.4 million in the prior quarter.
  • Over the last five years, Net Equity Issued and Repurchased for TARA reached as high as $48.3 million in Q4 2020 and fell as low as $105000.0 in Q1 2017.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 141.90 Mn
10 Protara Therapeutics 2.25 Mn 2.25 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2020 48.25 Mn
Dec 31, 2020 48.25 Mn
Mar 31, 2020 12.41 Mn
Mar 31, 2020 12.41 Mn
Dec 31, 2017 113,000.00
Dec 31, 2017 113,000.00
Jun 30, 2017 1.30 Mn
Jun 30, 2017 1.30 Mn
Mar 31, 2017 105,000.00
Mar 31, 2017 105,000.00